Updates in the management of relapsed/refractory multiple myeloma
| Autor: | Jenna Boudreau, Sarah Rose, Jenny Nguyen, Kirollos S Hanna, Sarah Tu, Samantha Larson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Antineoplastic Agents 03 medical and health sciences 0302 clinical medicine Maintenance therapy Refractory Internal medicine medicine Humans Pharmacology (medical) Multiple myeloma Isatuximab business.industry Antibodies Monoclonal medicine.disease Transplantation medicine.anatomical_structure 030220 oncology & carcinogenesis Relapsed refractory Bone marrow Stem cell Neoplasm Recurrence Local business Multiple Myeloma 030215 immunology |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 27(6) |
| ISSN: | 1477-092X |
| Popis: | Multiple myeloma, a malignant neoplasm of plasma cells that accumulate in bone marrow, accounts for approximately 18% of hematologic malignancies in the United States. Patients are often treated with triplet therapy and may undergo stem cell transplantation. Despite effective therapies, multiple myeloma remains incurable. Patients often require maintenance therapy, and many will progress or relapsed following upfront treatment. Selection of treatment in the relapse/refractory setting is complex due numerous active therapeutic agents and combinations. Treatment is often tailored to prior exposure and duration. In 2020, three novel pharmacological agents were approved in the relapsed setting. We highlight the clinical safety and efficacy of selinexor, isatuximab-irfc, and belantamab mafodotin for patients with multiple myeloma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|